Results 161 to 170 of about 4,267 (203)

Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach. [PDF]

Sci Rep
Shin DW, Cho JY, Cho S, Youn Y, Hwang JH.   +4 more
europepmc   +1 more source

Tubular Biomarkers and Retinal Microvasculature: Illuminating Early Cardiovascular-Kidney-Metabolic Pathways Beyond the Glomerulus. [PDF]

Kidney360
Cohen-Hagai K.
europepmc   +1 more source

Profibrinolytic Factors and Cancer Progression, Metastasis, and Survival. [PDF]

Arterioscler Thromb Vasc Biol
Hisada Y, Mackman N.
europepmc   +1 more source

Assessment of Cardiorenal Involvement in Systemic Sclerosis Patients. [PDF]

Biomolecules
Pellicano C, D'Ippolito G, Villa A, Martellucci O, Basile U, Carnazzo V, Basile V, Rosato E, Marino M, Gigante A.   +9 more
europepmc   +1 more source

Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

Scandinavian Journal of Clinical and Laboratory Investigation, 2020
suPAR is a plasma marker of chronic inflammation, and an elevated suPAR is consistently associated with worse outcome in a variety of clinical conditions. Quantification of suPAR is useful for determining patient risk in triage, but there is no fast automatized method for quick determination of suPAR.
Skovsted, Thor A., Petersen, Eva Rabing Brix, Fruekilde, Maj-Britt, Pedersen, Andreas Kristian, Pielak, Tomasz, Eugen-Olsen, Jesper   +5 more
openaire   +4 more sources

The Inflammatory Marker suPAR After Cardiac Arrest

Therapeutic Hypothermia and Temperature Management, 2015
Soluble urokinase plasminogen activator receptor (suPAR) is released in response to inflammatory stimuli, and plasma levels are associated with long-term outcomes. The ischemia/reperfusion injury caused by cardiac arrest (CA) and resuscitation triggers an inflammatory response. This pilot study aimed at investigating suPAR levels in relation to outcome
Malin, Rundgren, Stig, Lyngbaek, Helle, Fisker, Hans, Friberg   +3 more
openaire   +3 more sources

SuPAR, an emerging biomarker in kidney and inflammatory diseases [PDF]

Postgraduate Medical Journal, 2018
AbstractSoluble urokinase plasminogen activator receptor (suPAR) is a circulating form of a physiological and pathophysiological important cell surface receptor, implicated in inflammation. Recent studies showed that suPAR is a promising biomarker, useful for diagnosis, assessment and prognosis of several diseases.
Lamiaa Hamie, Georges Daoud, Georges Nemer, Tarek Nammour, Alissar El Chediak, Imad W Uthman, Abdul Ghani Kibbi, Assaad Eid, Mazen Kurban   +8 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

suPAR and chronic kidney disease—a podocyte story

Pflugers Archiv European Journal of Physiology, 2017
The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins.
Jochen Reiser, Jochen Reiser, Zeier Martin   +2 more
exaly   +3 more sources

SuPAR, a potential inflammatory mediator in psoriasis pathogenesis [PDF]

Clinical and Experimental Pharmacology and Physiology, 2020
Abstract Psoriasis is an inflammatory skin disorder that is strongly associated with the metabolic syndrome. The sole reliance on clinical examination to guide prognostication and treatment is insufficient at best; accurate diagnostic and prognostic psoriatic molecular biomarkers are needed.
Lamiaa Hamie, Edward Eid, Ossama Abbas, Remi Safi, Tarak Nammour, Hani Tamim, Maha Makki, Carla Stephan, Divina Hasbani, Hisham Wehbe, Nohra Ghaoui, Mariana Hawa, Nourhan Nasser, Assaad Eid, Abdul‐Ghani Kibbi, Mazen Kurban   +15 more
openaire   +3 more sources

An ELISA method detecting the active form of suPAR

Talanta, 2016
Urokinase plasminogen activator receptor (uPAR) exists in a number of formats in human plasma, including soluble uPAR (suPAR) and uPAR fragments. We developed an ELISA method to detect specifically the active form suPAR, which binds to its natural ligand uPA. The intra CV and inter CV of this ELISA assay is 8.5% and 9.6% respectively, and the assay can
Zafar Iqbal, Cai Yuan, Mingdong Huang
exaly   +3 more sources